Filing Flows › Halozyme Therapeutics (HALO) › Q3 2026
Halozyme Therapeutics (HALO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Halozyme Therapeutics (HALO) reported revenue of $493M for the third quarter 2026 (Q3 2026), +39% from a year earlier and +2% from the quarter before. Operating margin was 59.8%, net earnings $247M (50.1% of revenue).
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $493M | +2% | +39% |
| Operating profit | $295M | +3% | +35% |
| Net earnings | $247M | +7% | +41% |
| Operating cash flow | $258M | +7% | +45% |
| Free cash flow | $255M | +8% | +45% |
What changed
Revenue was $493.0M in Q3 2026, up 39% year over year and up 2% from the previous quarter. Royalties was the largest line at 69% of revenue. Royalties added $105.0M year over year (up 44%), 76% of the total change. Sales-based milestones declined 65%.
Operating profit was $295.0M, a 59.8% margin (down 1.7 points year over year). Of the extra revenue versus Q3 2025, 56% reached operating profit, below the 62% margin then. Total costs grew 45% against revenue growth of 39%. The fastest-growing cost line was Other operating costs (+66%). Net earnings were $247.0M, up 41% year over year. The effective tax rate was 15.0%.
Operating cash flow was $258.3M (up 45% year over year), 105% of net earnings. Non-cash charges added back $4.7M of depreciation and amortization and $16.8M of share-based compensation. Capital expenditures of $3.0M left free cash flow of $255.2M.
Questions
What was Halozyme Therapeutics' revenue in the third quarter 2026?
Halozyme Therapeutics (HALO) reported revenue of $493M for the third quarter 2026 (Q3 2026), +39% from a year earlier and +2% from the quarter before.
Was Halozyme Therapeutics profitable in the third quarter 2026?
Operating profit was $295M (59.8% of revenue) and net earnings $247M.